Peripheral blood derived gene panels predict response to infliximab in rheumatoid arthritis and Crohn's disease.

ABSTRACT:

Background

Biological therapies have been introduced for the treatment of chronic inflammatory diseases including rheumatoid arthritis (RA) and Crohn's disease (CD). The efficacy of biologics differs from patient to patient. Moreover these therapies are rather expensive, therefore treatment of primary non-responders should be avoided.

Method

We addressed this issue by combining gene expression profiling and biostatistical approaches. We performed peripheral blood global gene expression profiling in order to filter the genome for target genes in cohorts of 20 CD and 19 RA patients. Then RT-quantitative PCR validation was performed, followed by multivariate analyses of genes in independent cohorts of 20 CD and 15 RA patients, in order to identify sets ofinterrelated genes that

SUBMITTER: Mesko B 

PROVIDER: S-EPMC4064310 | biostudies-literature | 2013

REPOSITORIES: biostudies-literature